Cargando…

Preferential Cochleotoxicity of Cisplatin

Cisplatin-induced ototoxicity in humans is more predominant in the cochlea than in the vestibule. Neither definite nor substantial vestibular dysfunction after cisplatin treatment has been consistently reported in the current literature. Inner ear hair cells seem to have intrinsic characteristics th...

Descripción completa

Detalles Bibliográficos
Autores principales: Prayuenyong, Pattarawadee, Baguley, David M., Kros, Corné J., Steyger, Peter S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350121/
https://www.ncbi.nlm.nih.gov/pubmed/34381329
http://dx.doi.org/10.3389/fnins.2021.695268
_version_ 1783735686140002304
author Prayuenyong, Pattarawadee
Baguley, David M.
Kros, Corné J.
Steyger, Peter S.
author_facet Prayuenyong, Pattarawadee
Baguley, David M.
Kros, Corné J.
Steyger, Peter S.
author_sort Prayuenyong, Pattarawadee
collection PubMed
description Cisplatin-induced ototoxicity in humans is more predominant in the cochlea than in the vestibule. Neither definite nor substantial vestibular dysfunction after cisplatin treatment has been consistently reported in the current literature. Inner ear hair cells seem to have intrinsic characteristics that make them susceptible to direct exposure to cisplatin. The existing literature suggests, however, that cisplatin might have different patterns of drug trafficking across the blood-labyrinth-barrier, or different degrees of cisplatin uptake to the hair cells in the cochlear and vestibular compartments. This review proposes an explanation for the preferential cochleotoxicity of cisplatin based on current evidence as well as the anatomy and physiology of the inner ear. The endocochlear potential, generated by the stria vascularis, acting as the driving force for hair cell mechanoelectrical transduction might also augment cisplatin entry into cochlear hair cells. Better understanding of the stria vascularis might shed new light on cochleotoxic mechanisms and inform the development of otoprotective interventions to moderate cisplatin associated ototoxicity.
format Online
Article
Text
id pubmed-8350121
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83501212021-08-10 Preferential Cochleotoxicity of Cisplatin Prayuenyong, Pattarawadee Baguley, David M. Kros, Corné J. Steyger, Peter S. Front Neurosci Neuroscience Cisplatin-induced ototoxicity in humans is more predominant in the cochlea than in the vestibule. Neither definite nor substantial vestibular dysfunction after cisplatin treatment has been consistently reported in the current literature. Inner ear hair cells seem to have intrinsic characteristics that make them susceptible to direct exposure to cisplatin. The existing literature suggests, however, that cisplatin might have different patterns of drug trafficking across the blood-labyrinth-barrier, or different degrees of cisplatin uptake to the hair cells in the cochlear and vestibular compartments. This review proposes an explanation for the preferential cochleotoxicity of cisplatin based on current evidence as well as the anatomy and physiology of the inner ear. The endocochlear potential, generated by the stria vascularis, acting as the driving force for hair cell mechanoelectrical transduction might also augment cisplatin entry into cochlear hair cells. Better understanding of the stria vascularis might shed new light on cochleotoxic mechanisms and inform the development of otoprotective interventions to moderate cisplatin associated ototoxicity. Frontiers Media S.A. 2021-07-26 /pmc/articles/PMC8350121/ /pubmed/34381329 http://dx.doi.org/10.3389/fnins.2021.695268 Text en Copyright © 2021 Prayuenyong, Baguley, Kros and Steyger. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Prayuenyong, Pattarawadee
Baguley, David M.
Kros, Corné J.
Steyger, Peter S.
Preferential Cochleotoxicity of Cisplatin
title Preferential Cochleotoxicity of Cisplatin
title_full Preferential Cochleotoxicity of Cisplatin
title_fullStr Preferential Cochleotoxicity of Cisplatin
title_full_unstemmed Preferential Cochleotoxicity of Cisplatin
title_short Preferential Cochleotoxicity of Cisplatin
title_sort preferential cochleotoxicity of cisplatin
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350121/
https://www.ncbi.nlm.nih.gov/pubmed/34381329
http://dx.doi.org/10.3389/fnins.2021.695268
work_keys_str_mv AT prayuenyongpattarawadee preferentialcochleotoxicityofcisplatin
AT baguleydavidm preferentialcochleotoxicityofcisplatin
AT kroscornej preferentialcochleotoxicityofcisplatin
AT steygerpeters preferentialcochleotoxicityofcisplatin